0001593968-24-000614.txt : 20240424
0001593968-24-000614.hdr.sgml : 20240424
20240424161841
ACCESSION NUMBER: 0001593968-24-000614
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240422
FILED AS OF DATE: 20240424
DATE AS OF CHANGE: 20240424
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MOORE TIMOTHY L.
CENTRAL INDEX KEY: 0001669207
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38693
FILM NUMBER: 24870839
MAIL ADDRESS:
STREET 1: C/O KITE PHARMA, INC.
STREET 2: 2225 COLORADO AVE.
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allogene Therapeutics, Inc.
CENTRAL INDEX KEY: 0001737287
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 823562771
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 457-2700
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
primary_01.xml
PRIMARY DOCUMENT
X0508
4
2024-04-22
0001737287
Allogene Therapeutics, Inc.
ALLO
0001669207
MOORE TIMOTHY L.
210 EAST GRAND AVE
SOUTH SAN FRANCISCO
X1
94080
true
Chief Technical Officer
false
Common Stock
2024-04-22
4
F
false
17360
3.4671
D
265459
D
Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.44 to $3.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
/s/Earl Douglas, Attorney-in-Fact
2024-04-24